The company's revenues were driven by its centralized and point-of-care solutions as well as its molecular diagnostics business, both rising in the single digits.
The new schizophrenia risk genes, among them two encoding glutamate receptor subunits, appear to have some overlap with genes involved in autism spectrum disorder.
Within Diagnostics, year-over-year core laboratory Q3 revenues rose 8 percent to $1.18 billion but molecular diagnostics revenues fell 8 percent to $111 million.
The bank believes investors are too focused on the potential of PacBio's merger with Illumina falling through rather than recent developments regarding its technology.
Users can apply both companies' tools to view genomic evidence linked to disease mutations, reducing the time needed to examine a variant's pathogenicity.
The buccal epithelial cell-based epigenetic clock corresponded with age in those under 20, but skewed slightly higher in a small subset of children with autism spectrum disorder.
The project will provide approved researchers with access to samples and deidentified data collected from volunteer patients with Duchenne muscular dystrophy.
With the certification, the Silicon Valley-based company aims to roll out its AvaGen test for keratoconus and corneal dystrophies beginning this quarter.
Thousands of parent-child exomes helped researchers identify apparently causative mobile element insertions in a handful of children with developmental disorders.
The test, TruGraf, assesses differentially expressed genes in blood to rule out subclinical kidney transplant rejection in patients with stable renal function.
